probucol has been researched along with Diabetic Angiopathies in 5 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol, an agent characterized by lipid-lowering and antioxidant property, retards atherosclerosis effectively." | 7.81 | Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice. ( Dong, Z; Ge, J; Hu, K; Huang, W; Jin, X; Liu, G; Ma, X; Sun, A; Wang, K; Xu, F; Zhao, J; Zhu, H; Zou, Y, 2015) |
| "Probucol, an agent characterized by lipid-lowering and antioxidant property, retards atherosclerosis effectively." | 3.81 | Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice. ( Dong, Z; Ge, J; Hu, K; Huang, W; Jin, X; Liu, G; Ma, X; Sun, A; Wang, K; Xu, F; Zhao, J; Zhu, H; Zou, Y, 2015) |
| "Probucol treatment normalized CET in all subjects and significantly lowered plasma cholesterol (pre-Rx: 197±4." | 1.43 | Probucol normalizes cholesteryl ester transfer in type 2 diabetes. ( Bagdade, JD; Lane, JT; Subbaiah, PV, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, H | 1 |
| Jin, X | 1 |
| Zhao, J | 1 |
| Dong, Z | 1 |
| Ma, X | 1 |
| Xu, F | 1 |
| Huang, W | 1 |
| Liu, G | 1 |
| Zou, Y | 1 |
| Wang, K | 1 |
| Hu, K | 1 |
| Sun, A | 1 |
| Ge, J | 1 |
| Bagdade, JD | 1 |
| Lane, JT | 1 |
| Subbaiah, PV | 1 |
| Harada, Y | 1 |
| Colleran, R | 1 |
| Kufner, S | 1 |
| Giacoppo, D | 1 |
| Rheude, T | 1 |
| Michel, J | 1 |
| Cassese, S | 1 |
| Ibrahim, T | 1 |
| Laugwitz, KL | 1 |
| Kastrati, A | 1 |
| Byrne, RA | 1 |
| Bonnardel-Phu, E | 1 |
| Vicaut, E | 1 |
| Russell, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis[NCT00598533] | Phase 4 | 3,002 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for probucol and Diabetic Angiopathies
| Article | Year |
|---|---|
Type 2 diabetes: pharmacological intervention in an animal model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Calcium Channel Blockers; Diabe | 2001 |
1 trial available for probucol and Diabetic Angiopathies
| Article | Year |
|---|---|
Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Coronary Angiography; Coronary Restenosis; Cor | 2016 |
3 other studies available for probucol and Diabetic Angiopathies
| Article | Year |
|---|---|
Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR-/- Mice.
Topics: Animals; Aortic Diseases; Atherosclerosis; Biomarkers; CD11c Antigen; Cells, Cultured; Cholesterol; | 2015 |
Probucol normalizes cholesteryl ester transfer in type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Case-Control Studies; Cholesterol Es | 2016 |
[Role of oxidative stress in permeability changes observed in the microcirculation of diabetic rats in vivo].
Topics: Animals; Capillary Permeability; Catalase; Diabetes Mellitus, Experimental; Diabetic Angiopathies; D | 2000 |